Description
Ranavexim Pharmacodynamics
Sulfonamide is an antimicrobial bacteriostatic agent. Mechanism of action is associated with competitive antagonism with para-aminobenzoic acid (PABA) and inhibition of dihydropteroatsintase, which leads to disruption of dihydrofolic acid and then tetrahydrofolic acid synthesis, resulting in disruption of microbial nucleic acid synthesis. Active against Gram-positive and Gram-negative microorganisms: Escherichia coli, Shigella spp., Vibrio cholerae, Clostridium spp., Bacillus anthracis, Corynebacterium diphtheriae, Yersinia pestis, Chlamydia spp., Actinomyces spp., Toxoplasma gondii.
Indications
In the treatment of infected wounds, infected burns (I-II degree) and other inflammatory processes of soft tissue.
Contraindications .
Hypersensitivity to sulfonamides, hematopoietic diseases, suppression of medullary hematopoiesis, anemia, chronic heart failure, thyrotoxicosis, renal/liver failure, azotemia, porphyria, congenital deficiency of glucose-6-phosphate dehydrogenase, pregnancy, breast-feeding.
Caution: children under 3 years of age.
Administration during pregnancy and breast-feeding.
Contraindicated for use in pregnancy and breast-feeding.
Dosage and administration.
- Topically, as a powder for external use, applied directly to the affected surface, dressings are carried out every 1-2 days. Maximal doses for adults: single dose – 5 g, daily dose – 15 g.
- For children over 3 years old: single dose – 300 mg, daily dose – 300 mg.
- For deep wounds 5-10-15 g of powder for external use is applied to the wound cavity.
- Duration of the course of treatment is determined by the doctor taking into account the characteristics of the disease, tolerance of the drug and the effect achieved.
- If after treatment no improvement occurs or new symptoms appear, it is necessary to consult a doctor. Use the drug only according to the method of use and in the doses specified in the instructions. If necessary, please consult a physician before using the drug.
